Results 91 to 100 of about 5,935 (185)

Switch from abciximab to eptifibatide during percutaneous coronary intervention

, 2009
BACKGROUND: Treatment with glycoprotein (GP) IIb/IIIa inhibitors during percutaneous coronary intervention (PCI) reduce ischemic complications and improve outcome.
Grip, Lars,, Odell, Annika,, Tahmasebiepour, Farshad,, Karlsson, Thomas,, Matejka, Göran,, Albertsson, Per,, Wahlin, Magnus,, Wolmeryd, Christina,   +7 more
core  

Antiagregantes plaquetarios: mecanismos de acción y riesgos asociados al uso Platelet antiaggregants: mechanisms of action and use asocied risks

Vitae, 2009
Las Enfermedades Cardiovasculares son la principal causa de muerte en el mundo. Junto con los esfuerzos en disminuir los factores de riesgo cardiovascular, se recurre a diversos medicamentos para disminuir la morbimortalidad asociada a estas enfermedades,
Iván F PALOMO G, Constanza I TORRES U, Rodrigo E MOORE-CARRASCO, Marcelo A ALARCÓN L, Patricio J MARAGAÑO L   +4 more
doaj  

Los inhibidores de los receptores plaquetarios IIb/IIIa en los síndromes coronarios agudos. The IIb/IIIa platelet receptor inhibitors in the acute coronary syndromes.

Revista Cubana de Cardiología y Cirugía Cardiovascular, 2001
Los inhibidores de los receptores IIb/IIIa, un nuevo grupo de antiagregantes plaquetarios, son potentes bloqueadores del receptor que media la agregación plaquetaria y de ese modo bloquean la vía final común de la formación del trombo plaquetario.
Fidel Manuel Cáceres Lóriga, Horacio Pérez López   +1 more
doaj  

Glycoprotein IIb/IIIa Inhibitors Use and Outcome after Percutaneous Coronary Intervention for Non-ST Elevation Myocardial Infarction [PDF]

, 2014
J. P. Howard, C. Knight, Weerackody, R, Howard, JP, Antoniou, S, A. Mathur, Wragg, A, P. Wright, Knight, C, Rathod, K, R. Weerackody, S. Gallagher, S. Antoniou, K. Rathod, Jones, DA, D. A. Jones, A. Wragg, Gallagher, S, Wright, P, Mathur, A   +19 more
core   +1 more source

An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates

, 2012
BACKGROUND: The ability of abciximab to prevent fibrinogen binding to activated platelets indicates it may also promote dissolution of platelet-rich thrombi.
Marciniak, Stanley J. Jr., Frelinger, Andrew L. III, Jordan, Robert E., Marchese, Peter J., Furman, Mark I., Jakubowski, Joseph A., Mascelli, Mary A., Michelson, Alan D.   +7 more
core  

Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes [PDF]

, 2017
Aims The safety and efficacy of abciximab in addition to low-molecular-weight-heparin as the primary medical treatment of acute coronary syndromes has not previously been investigated.
James, S., Simoons, M.L., Kontny, F., Armstrong, P., Husted, S., Pfisterer, M., Niemminen, M., Wallentin, L., Califf, R.   +8 more
core  

PLATELET ANTIAGGREGANTS: MECHANISMS OF ACTION AND USE ASOCIED RISKS

Vitae, 2009
Cardiovascular diseases are the main cause of death in the world. Next to efforts to reduce the cardiovascular risk factors, several drugs are resorted to decrease morbimortality associated to these diseases: antihypertensive, antidiabetic, hypolipemiant
Iván F. PALOMO G, Constanza I. TORRES U., Rodrigo E. MOORE-Carrasco., Marcelo A. ALARCÓN L., Patricio J. MARAGAÑO L.   +4 more
doaj  

Economic Value of Platelet Glycoprotein IIb/IIIA Receptor Blocker (Abciximab) for Percutaneous Coronary Intervention

, 2007
This study was performed to analyse the economic value of abciximab which is used in PCI to prevent high-risk patients with ischemic complications. The effectiveness of abciximab was extracted from published clinical trials by search-ing CCIS, and the ...
신상진, 김진현, 이영희, 김은주   +3 more
core  

Abciximab [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

Revisiting Antiplatelet Therapy in Acute Carotid Tandem Lesions. [PDF]

J Clin Med
Zupan M, Straus L, Kermer P, Papanagiotou P, Frol S.   +4 more
europepmc   +1 more source